Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. As of May 21, 2025, Acelyrin, Inc. operates as a subsidiary of Alumis Inc. Show more
Location: 4149 Liberty Canyon Road, Agoura Hills, CA, 91301, United States | Website: https://www.acelyrin.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
229.2M
52 Wk Range
$1.84 - $7.25
Previous Close
$2.27
Open
$2.27
Volume
N/A
Day Range
$2.27 - $2.27
Enterprise Value
-174.4M
Cash
410.6M
Avg Qtr Burn
-71.39M
Insider Ownership
7.15%
Institutional Own.
91.98%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lonigutamab Details Thyroid Eye Disease , Eye disease | Phase 3 Initiation | |
Izokibep Details Axial spondyloarthritis | Failed Discontinued | |
Izokibep Details Psoriatic arthritis | Failed Discontinued | |
SLRN-517 Details Allergy, Inflammatory disease, KIT/Mast cell diseases | Failed Discontinued | |
Izokibep Details Uveitis , Eye disease | Failed Discontinued | |
Izokibep Details Hidradenitis suppurativa | Failed Discontinued |